Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options

  Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options   Tevogen’s investigational precision T cell product, TVGN-489, is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple precise targets across the entireContinue reading “Tevogen Bio to Study its Investigational COVID-19 T Cell Therapy in Immunocompromised Patients Who are Unable to Benefit From Currently Available Prevention or Treatment Options”

Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis

  Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis   Given that no dose limiting toxicities or treatment-related adverse events were observed during Tevogen’s proof-of-concept trial, in patients with SARS-CoV-2 infection, the company plans to develop target specific genetically unmodified T cell therapies for the treatmentContinue reading “Tevogen Bio to Develop T Cell Therapies for Treatment of Epstein-Barr Virus Related Cancers and Multiple Sclerosis”

Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID

  Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID   Tevogen’s investigational precision T cell product, TVGN 489, is designed to address the unmet need of COVID-19 patients who are unable to take or unlikely to benefit from currently available prevention or treatment strategies and potentially thoseContinue reading “Tevogen Bio to Study Therapeutic Potential of its Investigational COVID-19 T Cell Therapy in Long COVID”

Tevogen Bio’s CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg share President Biden’s concerns

  Tevogen Bio CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg share White House concerns about emerging COVID-19 variants and their impact on immunocompromised patients, and express the company’s commitment to accelerate development of its investigational COVID-19 therapy   Tevogen Bio CEO and CSO share concerns of the White House and PresidentContinue reading “Tevogen Bio’s CEO Dr. Ryan Saadi and Chief Scientific Officer Dr. Neal Flomenberg share President Biden’s concerns”

Tevogen Bio Expresses Gratitude for 2023 Nobel Peace Prize Nomination

  Tevogen Bio® Expresses Gratitude for 2023 Nobel Peace Prize Nomination of the Company and its Founding CEO Ryan Saadi in Recognition of its Novel Business Model to Alleviate Health Inequality   Tevogen Bio and Founding CEO are nominated for the 2023 Nobel Peace Prize by Curtis Patton, PhD, Professor Emeritus, Yale School of PublicContinue reading “Tevogen Bio Expresses Gratitude for 2023 Nobel Peace Prize Nomination”

Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board

  Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board   Victor Sordillo, PE, CSP, MBA, joins Tevogen Bio’s Corporate Advisory Board   The appointment of Sordillo contributes to the diversity of thought leadership within Tevogen Bio’s executive team by way of expertise in leadership, risk management, and financeContinue reading “Tevogen Bio Appoints Esteemed Global Safety Management Expert Victor Sordillo to its Corporate Advisory Board”

Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors

  Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors   New Board members include Susan Podlogar, M.B.A., Jeffrey Feike, M.P.H., and Lindee Goh, Ph.D. A full list of the Board of Directors can be found on Tevogen’s website   Tevogen Bio CEO Ryan Saadi, M.D., M.P.H., and Curtis Patton, Ph.D., ProfessorContinue reading “Tevogen Bio Appoints Three Prominent Healthcare Leaders to its Board of Directors”

Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment

  Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment in Proof-of-Concept Clinical Trial of T cell Therapy for Elderly or High-Risk COVID-19 Patients   No dose-limiting toxicities or significant treatment-related adverse events were observed for any patient at any dose level       August 1, 2022   WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio,Continue reading “Tevogen Bio Announces Positive Safety Results Upon Completion of Patient Enrollment”

Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D

  Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D   Acclaimed oncologist and immunotherapy expert Neal Flomenberg, M.D. joins Tevogen Bio as Chief Scientific Officer (CSO) and Global Head of Research & Development   Dr. Flomenberg most recently served as Professor and ChairmanContinue reading “Tevogen Bio Appoints Acclaimed Oncologist and Immunotherapy Expert Neal Flomenberg, M.D. as Chief Scientific Officer and Global Head of R&D”

Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology

  Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology   Tevogen Bio’s new Research and Development Center is located in Philadelphia’s Wanamaker Office Building Strategic location of the R&D Center compliments Tevogen’s research facility at CIC Philadelphia as the company expands its precision T cell product pipeline inContinue reading “Tevogen Bio Establishes Philadelphia R&D Center to Expedite Product Development in Oncology, Neurology, and Virology”